Drug Trial Radar · NCT06466135
Study of WAL0921 in Patients With Glomerular Kidney Diseases
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Jul 2, 2024
Primary completion
Mar 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Walden BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Jun 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \[FSGS\], treatment-resistant minimal change disease \[TR MCD\], primary immunoglobulin A nephropathy \[IgAN\], and primary membranous nephropathy \[PMN\]). Subjects in this study will be randomized to receive the investigational drug WAL0921 or placebo as an intravenous infusion once every 2 weeks for 7 total infusions. All subjects will be followed for 24 weeks after their last infusion.
Conditions
- Diabetic Nephropathies
- Primary Focal Segmental Glomerulosclerosis
- Minimal Change Disease
- Primary Immunoglobulin A Nephropathy
- Primary Membranous Nephropathy
Interventions
WAL0921Drug
Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.
PlaceboDrug
Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse eventsTime frame: Baseline to Week 36
Locations
50 sites in 7 countries. Site status is shown where the registry gives one.
Academic Medical Research Institute
Los Angeles, California · Recruiting
Colorado Kidney and Vascular Care
Denver, Colorado · Recruiting
D & H Tamarac Research Center
Tamarac, Florida · Recruiting
Fides Clinical Research
Atlanta, Georgia · Recruiting
Nephrology Associates of Northern Illinois and Indiana (NANI)
Hinsdale, Illinois · Recruiting
Dunes Clinical Research
Dakota Dunes, South Dakota · Recruiting
Prolato Clinical Research Center
Houston, Texas · Recruiting
Clinical Trial Network
Houston, Texas · Recruiting
Clinical Advancement Center
San Antonio, Texas · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Western Health Sunshine Hospital
St Albans, Victoria, Australia · Recruiting
AIIMS Hospital
Raipur, Chhattisgarh, India · Active not recruiting
Muljibhai Patel Urological Hospital
Nadiād, Gujarat, India · Active not recruiting
Dhiraj Hospital
Vadodara, Gujarat, India · Active not recruiting
MS Ramaiah Medical College and Hospitals
Bangalore, Karnataka, India · Active not recruiting
Mazumdar Shah Medical Center
Bangalore, Karnataka, India · Active not recruiting
Manipal Hospital
Pune, Maharashtra, India · Active not recruiting
MGM Medical Care and Hospital
Sambhajinagar, Maharashtra, India · Active not recruiting
Sir Ganga Ram Hospital
New Delhi, National Capital Territory of Delhi, India · Active not recruiting
Max Super Speciality Hospital
Patparganj, National Capital Territory of Delhi, India · Active not recruiting
SUM Hospital
Bhubaneswar, Odisha, India · Active not recruiting
SMS Medical College and Hospital
Jaipur, Rajasthan, India · Active not recruiting
Osmania General Hospital
Hyderabad, Telangana, India · Active not recruiting
Nizam's Institute of Medical Sciences
Hyderabad, Telangana, India · Active not recruiting
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Lucknow, Uttar Pradesh, India · Active not recruiting
Nutema Hospital
Meerut, Uttar Pradesh, India · Active not recruiting
Shri Guru Ram Rai Institute of Medical and Health Sciences
Dehradun, Uttarakhand, India · Active not recruiting
NRS Medical College and Hospital Kolkata
Kolkata, West Bengal, India · Active not recruiting
Hospital Canselor Tuanku Muhriz UKM
Cheras, Kuala Lumpur, Malaysia · Recruiting
Hospital Kuala Lumpur
Kuala Lumpur, Kuala Lumpur, Malaysia · Recruiting
University Malaya Medical Centre
Kuala Lumpur, Kuala Lumpur, Malaysia · Recruiting
Hospital Tengku Ampuan Afzan
Kuantan, Pahang, Malaysia · Recruiting
Hospital Sultan Idris Shah Serdang
Kajang, Selangor, Malaysia · Recruiting
Sunway Medical Centre
Petaling Jaya, Selangor, Malaysia · Recruiting
Hallym University Sacred Heart Hospital
Anyang, South Korea · Recruiting
Pusan National University Hospital
Busan, South Korea · Recruiting
Seoul National University Bundang Hospital
Seongnam-si, South Korea · Recruiting
Severance Hospital - Yonsei Cancer Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Soeul, South Korea · Recruiting
Ajou University Hospital
Suwon, South Korea · Recruiting
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.